Details for Patent: 9,382,217
✉ Email this page to a colleague
Which drugs does patent 9,382,217 protect, and when does it expire?
Patent 9,382,217 protects ZEPOSIA and is included in one NDA.
This patent has forty-eight patent family members in twenty-six countries.
Summary for Patent: 9,382,217
Title: | Modulators of sphingosine phosphate receptors |
Abstract: | Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided. |
Inventor(s): | Roberts; Edward (Fallbrook, CA), Rosen; Hugh (La Jolla, CA), Brown; Steven (San Diego, CA), Guerrero; Miguel A. (San Diego, CA), Peng; Xuemei (La Jolla, CA), Poddutoori; Ramulu (La Jolla, CA) |
Assignee: | The Scripps Research Institute (La Jolla, CA) |
Application Number: | 14/311,825 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,382,217
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-001 | Mar 25, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS | ⤷ Try a Trial | ||||
Bristol | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-002 | Mar 25, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS | ⤷ Try a Trial | ||||
Bristol | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-003 | Mar 25, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,382,217
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | E542389 | ⤷ Try a Trial | |||
Australia | 2009258242 | ⤷ Try a Trial | |||
Australia | 2015213309 | ⤷ Try a Trial | |||
Brazil | PI0912545 | ⤷ Try a Trial | |||
Canada | 2723904 | ⤷ Try a Trial | |||
China | 102118972 | ⤷ Try a Trial | |||
Cyprus | 2020033 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |